Repare Therapeutics (NASDAQ:RPTX) Given “Buy” Rating at HC Wainwright

Repare Therapeutics (NASDAQ:RPTX)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $10.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 177.78% from the stock’s current price.

Separately, Lifesci Capital raised shares of Repare Therapeutics to a “strong-buy” rating in a research report on Monday, July 29th.

Repare Therapeutics Stock Performance

Shares of RPTX traded up $0.11 during midday trading on Friday, hitting $3.60. 17,345 shares of the company traded hands, compared to its average volume of 161,953. Repare Therapeutics has a 52 week low of $2.71 and a 52 week high of $8.49. The firm has a 50 day moving average of $3.34 and a 200-day moving average of $3.39. The stock has a market cap of $152.82 million, a price-to-earnings ratio of -2.20 and a beta of 0.72.

Repare Therapeutics (NASDAQ:RPTX) last issued its earnings results on Tuesday, August 6th. The company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.03. The business had revenue of $1.07 million for the quarter, compared to analyst estimates of $4.02 million. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 31.11%. Sell-side analysts predict that Repare Therapeutics will post -2.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Repare Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC lifted its position in Repare Therapeutics by 212.1% during the second quarter. Acadian Asset Management LLC now owns 417,929 shares of the company’s stock valued at $1,373,000 after purchasing an additional 284,036 shares during the period. Blue Owl Capital Holdings LP lifted its position in Repare Therapeutics by 8.0% during the second quarter. Blue Owl Capital Holdings LP now owns 3,372,499 shares of the company’s stock valued at $11,129,000 after purchasing an additional 250,000 shares during the period. Squarepoint Ops LLC lifted its position in Repare Therapeutics by 428.4% during the second quarter. Squarepoint Ops LLC now owns 142,974 shares of the company’s stock valued at $472,000 after purchasing an additional 115,916 shares during the period. Renaissance Technologies LLC lifted its position in Repare Therapeutics by 30.7% during the second quarter. Renaissance Technologies LLC now owns 458,700 shares of the company’s stock valued at $1,514,000 after purchasing an additional 107,700 shares during the period. Finally, Marshall Wace LLP acquired a new position in Repare Therapeutics during the second quarter valued at $273,000. 85.09% of the stock is currently owned by institutional investors and hedge funds.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.